The Biologics License Application (BLA) of ZymoGenetics, Inc. (Nasdaq: ZGEN) for recombinant human thrombin (rhThrombin) has been accepted by the USFDA.
A recombinant form of human thrombin that is not derived from animal or human blood, rhThrombin is being developed by ZymoGenetics as a general aid to achieving hemostasis during surgery.
According to Bruce L.A. Carter, President and Chief Executive Officer of ZymoGenetics:
Read the full report."We're extremely pleased that the FDA accepted our Biologics License Application for rhThrombin for review. In the past, recombinant products have quickly replaced animal and human plasma products, so we're excited about the potential opportunity to compete in the thrombin market.
We believe based on our market research that we can attain a substantial share of the existing bovine thrombin market and that there is significant potential to grow the use of thrombin in surgical procedures through increased awareness."
Comment Preview